In the multivariate regression model, independent predictors of serum hepcidin levels in ESRD patients before maintenance dialysis were interleukin-6, ferritin, phosphate, iron, and aspartate transaminase.
Interaction between gender and <i>HFE</i> haplotypes for the hepcidin-25 and ferritin levels in ESRD patients (<i>p</i> = 0.005, partial eta squared = 0.09; <i>p</i> = 0.027, partial eta squared = 0.06, respectively) was found.
Liver iron is a major regulator of hepcidin gene expression via BMP/SMAD pathway in a rat model of chronic renal failure under treatment with high rHuEPO doses.
Hepcidin has been identified as an important contributor to morbidity and mortality in end stage renal disease (ESRD) but no such association has jet been found in case of PTA.
Increased serum hepcidin has been reported in patients receiving chronic hemodialysis, and hypothesized to contribute to the alterations of iron metabolism of end-stage renal disease.